I dont think releasing an acknowledgment just to make some share holders feel better is a valid reason to do it.
SH know the potential of the drug and the long term $ potential, what is needed is data and then more data to be released, and in due course and at the most appropriate time, the data will come. This is what would be well met by shareholders, potential shareholders, big pharma and the market overall, not a ‘ribbon for participation”.
Ann: New Collaboration to Understand Zantrene Cardioprotection, page-87
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.050(3.17%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.59 | $1.51 | $174.6K | 113.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2372 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 141 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |